Drug Profile
Research programme: HIV protease inhibitors - Medivir/Tibotec
Alternative Names: HIV-PI therapeutics - Medivir/Tibotec Pharmaceuticals/J&JLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Medivir AB
- Developer Janssen R&D Ireland; Medivir AB
- Class
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Sweden
- 17 Mar 2011 This research programme is ongoing in Sweden
- 07 Jan 2008 Medivir and Tibotec extend their collaboration for a further year